ClinicalTrials.gg
RecruitingNCT05429632MO-TRANSUpdated Oct 30, 2026

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

A Phase 3 interventional study of mocravimod in Adult Acute Myeloid Leukemia, sponsored by Priothera SAS. Recruiting at 111 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Priothera SAS · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Oct 30, 2026Site recruiting status changed5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
69th of 1,907
366 · median 35
Started
2022
with 80 others
Phase 3
122 of 2,137
8 open now
Primary completion
2027-05
later than 209 of 464 live
Registered
1,856th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 69th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 81 that started in 2022, is one of 122 in phase 3, reaches primary completion later than 209 of the 464 other live ones, and was the 1,856th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT).

03

Conditions studied

  • Adult Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations
  • European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, [CRi] is also allowable
  • Planned HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft
  • Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5
  • Planned use of TAC-based GvHD prophylaxis
  • age ≥ 18 years and ≤ 75 years
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Use of CsA, anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis
  • Diagnosis of macular edema during screening
  • Cardiac/pulmonary/hepatic/renal dysfunction
  • Hepatic dysfunction as defined by (AST) and/or alanine aminotransferase (ALT) > 2.5 x (ULN); or total > 1.5 mg/dL
  • Renal dysfunction with estimated \< 45 mL/min by the Cockcroft-Gault formula

    • Diabetes mellitus
    • History or presence of uveitis at screening
    • History or diagnosis of macular edema
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (estimated)

Study arms

  • Experimental
    3mg mocravimod arm

    3 mg of mocravimod orally once per day for 12 months

    Drug: mocravimod

  • Experimental
    1mg mocravimod arm

    1 mg of mocravimod orally once per day for 12 months

    Drug: mocravimod

  • Placebo comparator
    Placebo arm

    placebo orally once per day for 12 months

    Drug: mocravimod

Interventions

06

What researchers measure

Primary outcomes

  1. Relapse-free survival (RFS)

    To compare the efficacy of mocravimod to that of placebo

    Time frame: 12 months

Secondary outcomes

  1. Overall survival (OS)

    To compare mocravimod's effect on overall survival (OS) to that of placebo

    Time frame: 24 months

07

Study locations

64 of 111 sites recruiting

Showing the first 100 of 111 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2027, 59 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 59 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jun 23, 2022
StartActual
Jun 16, 2022
Primary completionEst.
May 2027
CompletionEst.
Nov 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed. 2 sites changed recruiting status (2 now withdrawn)
Show 2 sites
  • Institutul Clinic Fundeni · Bucharest, RomaniaRecruiting→Withdrawn
  • Universitaetsspital Basel · Basel, SwitzerlandRecruiting→Withdrawn
Show 5 added (3 Italy, 1 Israel, 1 Japan)
  • The Chaim Sheba Medical Center · Tel HaShomer, Israel
  • Azienda Sanitaria Localedella provincia di Brindisi - · Brindisi, Italy
  • Ospedale Vito Fazzi Lecce · Lecce, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
  • Jichi Medical University Saitama Medical Center · Saitama, Japan
Show 5 removed
  • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
  • Azienda Sanitaria Localedella provincia di Brindisi - · Brindisi, Italy
  • Ospedale Vito Fazzi Lecce · Lecce, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
  • Jichi Medical University Saitama Medical Center · Saitama, Japan
Oct 30, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Osaka Metropolitan University Hospital · Osaka, JapanContact added (no phone or email listed)
  • Institutul Clinic Fundeni · Bucharest, RomaniaContact removed a•••@yahoo.com · •••2055
  • Universitaetsspital Basel · Basel, SwitzerlandContact removed F•••@usb.ch
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    5 sites added, 5 sites removed. 2 sites changed recruiting status (2 now withdrawn)
    Show 2 sites
    • Institutul Clinic Fundeni · Bucharest, RomaniaRecruiting→Withdrawn
    • Universitaetsspital Basel · Basel, SwitzerlandRecruiting→Withdrawn
    Show 5 added (3 Italy, 1 Israel, 1 Japan)
    • The Chaim Sheba Medical Center · Tel HaShomer, Israel
    • Azienda Sanitaria Localedella provincia di Brindisi - · Brindisi, Italy
    • Ospedale Vito Fazzi Lecce · Lecce, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
    • Jichi Medical University Saitama Medical Center · Saitama, Japan
    Show 5 removed
    • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
    • Azienda Sanitaria Localedella provincia di Brindisi - · Brindisi, Italy
    • Ospedale Vito Fazzi Lecce · Lecce, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italy
    • Jichi Medical University Saitama Medical Center · Saitama, Japan
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Osaka Metropolitan University Hospital · Osaka, JapanContact added (no phone or email listed)
    • Institutul Clinic Fundeni · Bucharest, RomaniaContact removed a•••@yahoo.com · •••2055
    • Universitaetsspital Basel · Basel, SwitzerlandContact removed F•••@usb.ch

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05429632
Lead sponsor
Priothera SAS
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Jun 16, 2022
Primary completion
May 2027 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Malika Souquieres, MSc
Contact
malika.souquieres@priothera.com
+33 (0) 6 40 91 26 76
Jens Hasskarl, MD
Contact
jens.hasskarl@priothera.com
+41 79 5432099
Marcos DeLima, MD
principal investigator · The Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRP-203

Start the discussion